AcelRx Pharmaceuticals (NSDQ:ACRX) touted device functionality outcomes today from the Phase III trial of its Zalviso drug-device combination product.
Zalviso is designed to deliver a sublingual formulation of an opioid, sufentanil, to adult patients with moderate-to-severe pain in a hospital setting using a hand-held, pre-programmed system. The device allows patients to self-administer sufentanil as often as once every 20 minutes.
Get the full story at our sister site, Drug Delivery Business News.
The post AcelRx’s pain relief drug-device combo succeeds in late-stage trial appeared first on MassDevice.